What question did this study set out to answer?

The aim is to evaluate AUTO1, a novel CD19 CAR, in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL).

November 4, 2020Blood

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

View Full Paper

Ask AI

Bookmark

The aim is to evaluate AUTO1, a novel CD19 CAR, in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL).
24 patients underwent leukapheresis and 19 received at least one dose of AUTO1.
Patients aged >16y received lymphodepletion with fludarabine and cyclophosphamide before CAR T-cell infusion.
Study endpoints included manufacture feasibility, toxicity, and remission rates at 1 and 3 months.
16 out of 19 infused patients (84%) achieved minimal residual disease negative complete response.
Event-free survival at 6 months was 62%, and 76% for the closed process manufacturing.
No patients experienced grade 3 or higher cytokine release syndrome, with only 3 experiencing grade 3 ICANS.

No takes yet. Share an insight, caveat, or question.

Randomized trial reports high remission rates in adult relapsed/refractory B-ALL using AUTO1 therapy, suggesting potential as a standalone treatment.

Roddie et al. (2020) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial reports high remission rates in adult relapsed/refractory B-ALL using AUTO1 therapy, suggesting potential as a standalone treatment.